PDCD1 and melanoma: Furthermore, the occurrence of irAEs and the possibility of detecting them on PET may be an additional factor predicting response to immunotherapy, given the evidence that irAEs are associated with the efficacy of PD1 inhibitors in patients with melanoma or NSCLC [40, 41].